Hiroko Matuura (Hiroko Matsuura)

Publication Activity (10 Years)

Years Active: 2017-2020
Publications (10 Years): 4

Top Topics

Long Non Coding Rna

Combination Therapy

Endometrial Cancer

Top Venues

Cancer chemotherapy and pharmacology

Medical oncology (Northwood, London, England)

Pathology oncology research : POR

This page only lists publications with an associated author ORCID identifier.

Publications

Soichiro Kakimoto, Morikazu Miyamoto, Takahiro Einama, Hiroko Matuura, Hideki Iwahashi, Hiroki Ishibashi, Takahiro Sakamoto, Taira Hada, Masashi Takano
Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma. Pathology oncology research : POR 26 (4) (2020)
Kazuki Takasaki, Morikazu Miyamoto, Masashi Takano, Hiroaki Soyama, Tadashi Aoyama, Hiroko Matuura, Kento Kato, Takahiro Sakamoto, Mika Kuwahara, Hideki Iwahashi, Hiroki Ishibashi, Tomoyuki Yoshikawa, Kenichi Furuya
Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. Cancer chemotherapy and pharmacology 81 (5) (2018)
Morikazu Miyamoto, Masashi Takano, Mika Kuwahara, Hiroaki Soyama, Kento Kato, Hiroko Matuura, Takahiro Sakamoto, Kazuki Takasaki, Tadashi Aoyama, Tomoyuki Yoshikawa, Kenichi Furuya
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review. Cancer chemotherapy and pharmacology 81 (1) (2017)
Hiroaki Soyama, Morikazu Miyamoto, Masashi Takano, Tadashi Aoyama, Hiroko Matuura, Takahiro Sakamoto, Kazuki Takasaki, Mika Kuwahara, Kento Kato, Tomoyuki Yoshikawa, Hideki Iwahashi, Hitoshi Tsuda, Kenichi Furuya
Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin. Medical oncology (Northwood, London, England) 34 (12) (2017)